comparemela.com
Home
Live Updates
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring : comparemela.com
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis, Inc. announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for...
Related Keywords
California ,
United States ,
Hebron ,
Israel General ,
Israel ,
London ,
City Of ,
United Kingdom ,
Chicago ,
Illinois ,
Fremont ,
American ,
Richard Chen ,
Rodrigo Toledo ,
Isaac Garcia Murillas ,
Adrienne Waks ,
Nicholas Turner ,
Mandy Nixon ,
Linkedin ,
Product Service ,
Duke Cancer Institute ,
Us National Cancer Institute ,
Dana Farber Cancer Institute ,
Institute Of Cancer Research ,
Hebron Institute Of Oncology ,
American Society For Clinical Oncology ,
Nasdaq ,
Personalis Inc ,
Exchange Commission ,
Conference Call ,
Early Stage Breast Cancer Recurrence Detection ,
American Society ,
Clinical Oncology ,
Cancer Institute ,
Cancer Research ,
Royal Marsden ,
Professor Nicholas Turner ,
Hebron Institute ,
Professor Andy Nixon ,
Chief Medical Officer ,
Private Securities Litigation Reform Act ,
Financial Condition ,
Personali Annual Report ,
Quarterly Report ,
comparemela.com © 2020. All Rights Reserved.